Parietal cell (highly selective or proximal gastric) vagotomy for peptic ulcer disease.
Parietal cell vagotomy has been in clinical use for 7 years in elective treatment of nonobstructive duodenal ulcer, and for even a shorter period for complicated cases and for gastric ulcer The evolution of the surgical technique has not yet come to an end and the ability to perform the procedure is still improving. It can therefore be questioned, if this operation is yet ripe for a realistic clinical trial, and the great variation in recurrence rate reported in pilot series as well as in prospective randomized clinical trials points to the possibility that we will have to wait several years before the anticipated mean recurrence rate is known. At present it can be stated that even if gastric emptying is not quite undisturbed, the addition of a drainage procedure in nonobstructive cases is unnecessary. The same may be true in some patients with pyloric obstruction. Furthermore, the mortality rate is very low and the incidence of moderate-to-severe dumping and diarrhea is virtually nil.
D000818:Animals; D002986:Clinical Trials as Topic; D003718:Denmark; D003967:Diarrhea / Q000209:etiology; D004322:Drainage; D004377:Dumping Syndrome / Q000209:etiology; D004381:Duodenal Ulcer / Q000150:complications / Q000401:mortality / Q000601:surgery; D005750:Gastric Juice / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D005769:Gastrointestinal Motility; D006801:Humans; D010437:Peptic Ulcer / Q000401:mortality / Q000601:surgery*; D010865:Pilot Projects; D011183:Postoperative Complications; D011707:Pyloric Stenosis / Q000209:etiology / Q000601:surgery; D012008:Recurrence; D013270:Stomach / Q000473:pathology* / Q000503:physiopathology; D013276:Stomach Ulcer / Q000401:mortality / Q000601:surgery; D014628:Vagotomy / Q000379:methods*
D005755:Gastrins